EPZM News and Press, Epizyme Inc. From 05/04/20

Epizyme ( EPZM ) Q1 results : More news on: Epizyme, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...

Epizyme (NASDAQ: EPZM ): Q1 GAAP EPS of -$0.51 beats by $0.21 . More news on: Epizyme, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

TAZVERIK™ Successfully Launched for First Approved Indication; PDUFA Date of June 18, 2020 for sNDA for Follicular Lymphoma Indication Business Continuity Plans in Place in Response to COVID-19 Conference Call to be Held Today, May 4 at 9:00 a.m. ET Epizyme , (Nasdaq:...

Epizyme, Inc . (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Mo...

The Food and Drug Administration (FDA) made numerous drug approval decisions in the first quarter. These binary events can cause stock prices to skyrocket or plummet depending on the outcome. Here we explore four companies that successfully attained FDA approval. It marked the first drug ever...

Shares of Epizyme (NASDAQ: EPZM) dropped more than 27% last month, according to data from  S&P Global Market Intelligence . The tumble marked an abrupt end to a rally that extended back to October 2019. Shares nearly doubled from October to the beginning of March as investors cheere...

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James. More news on: Apellis Pharmaceuticals, Inc., BioXcel Therapeutics, Inc., Eidos Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

"About all I can say for the United States Senate is that it opens with a prayer and closes with an investigation ." - Will Rogers Today, we look at an interesting small-cap concern making the transition into commercialization after a recent FDA approval. Like about everything in the mark...

Epizyme, Inc . (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the company has appointed Jeffery Kutok, M.D., Ph.D., as chief scientific officer. In this role, Dr. Kutok will direct the company’...

For those with cash on the sidelines, the precipitous market drop means there are currently some promising companies at attractive prices. Let's delve into three exciting cancer drug developers worth strong consideration. One has successfully commercialized its cancer drug and is expanding its ...